Search results
Showing 2221 to 2235 of 2581 results for methods
Discontinued Reference number: GID-TA10531
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Discontinued Reference number: GID-TA10933
Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]
Discontinued Reference number: GID-TAG420
Discontinued Reference number: GID-TAG368
Discontinued Reference number: GID-TA10567
In development Reference number: GID-TA10391 Expected publication date: TBC
In development Reference number: GID-TA10745 Expected publication date: 17 July 2024
Biographies for all current members of the diagnostics advisory committee.
Biographies for all current members of the diagnostics advisory committee.
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244
Discontinued Reference number: GID-TA10512
Discontinued Reference number: GID-TA10583
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued Reference number: GID-TA10321